Editas Medicine, Inc. EDIT announced data from the phase I/II BRILLIANCE study evaluating its lead pipeline candidate, EDIT-101, for treating blindness due to Leber congenital amaurosis type 10 (LCA10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback